Hypothesis: A promising effect of 5-HT1A receptor agonists in alleviating motor symptoms of parkinson's disease

African Journal of Pharmacy and Pharmacology

Volumn 4, Issue 6, 2010, Pages 289-290

  Nayebi, A M ^a  

^a TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

5 HT1A; Motor symptom; Parkinson disease; Receptor

Indexed keywords

ANTIPARKINSON AGENT; BUSPIRONE; DOPAMINE 2 RECEPTOR BLOCKING AGENT; HALOPERIDOL; LEVODOPA; SEROTONIN 1A AGONIST; SEROTONIN 1A RECEPTOR;

ADJUVANT THERAPY; ARTICLE; BASAL GANGLION; DOPAMINE RELEASE; DORSAL RAPHE NUCLEUS; DYSKINESIA; HUMAN; MOTOR DYSFUNCTION; PARKINSON DISEASE; SEROTONIN RELEASE; STRIATONIGRAL DEGENERATION;

EID: 77954668328     PISSN: None     EISSN: 19960816     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Bara-Jimenez W, Bibbiani F, Morris MJ, Dimitrova T, Sherzai A, Mouradian MM, Chase TN (2005). Effects of serotonin 5-HT1A agonist in advanced Parkinson's disease. Mov. Disord., 20: 932-936.
2. Benloucif S, Galloway MP (1991). Facilitation of dopamine release in vivo by serotonin agonists: studies with microdialysis. Eur. J. Pharmacol., 200: 1-8.
3. De Deurwaerdere P, Navailles S, Berg KA, Clark WP, Spampinato U (2004). Constitutive activity of the serotonin 2C receptor inhibits in vivo dopamine release in the rat striatum and nucleus accumbens; J. Neurosci., 24: 3235-41.
4. Dupre KB, Eskow KL, Negron G, Bishop C (2007). The differential effects of 5-HT1A receptor stimulation on dopamine receptor-mediated abnormal involuntary movements and rotations in the primed hemiparkinsonian rat. Brain Res., 1158: 135-143.
5. Hamon M, Fattaceini CM, Adrien J, Gallissot MC, Martin P, Gozlan H (1988). Alterations of central serotonin and dopamine turnover in rats treated with ipsapirone and other 5-hydroxytryptamine1A agonists with potential anxiolytic properties; J. Pharmacol. Exp. Ther., 246: 745-752.
6. Ichikawa J, Meltzer HY (1999). R(+)-8-OH-DPAT, a serotonin1A receptor agonist, potentiated S(-)-sulpiride-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens but not striatum; J. Pharmacol. Exp. Ther., 291: 1227-1232.
7. Knobelman DA, Kung HF, Lucki I (2000). Regulation of extracellular concentrations of 5-hydroxytryptamine (5-HT) in mouse striatum by 5- HT(1A) and 5-HT(1B) receptors; J. Pharmacol. Exp. Ther., 292: 1111-1117.
8. Mignon L, Wolf WA (2007). Postsynaptic 5-HT1A receptor stimulation increases motor activity in the 6-hydroxydopamine-lesioned rat: implications for treating Parkinson's disease. Psychopharmacology, 192: 49-59.
9. Miyawaki E, Meah Y, Koller WC (1997). Serotonin, dopamine, and motor effects in parkinson's disease. Clin. Neuropharmacol., 20: 300-310.
10. Nayebi MA, Reyhani Rad S, Saberian M, Azimzadeh S, Samini M (2010). Buspirone improves 6-hydroxydopamine-induced catalepsy through stimulation of nigral 5-HT1A receptors in rat. Pharmacol. Reports. 62: 2.
11. Riad M, Garcia S, Watkins KC, Jodoin N, Doucet E, Langlois X, Mestikawy S, Hamon M, Descarries L (2000). Somatoendritic localization of 5-HT1A and preterminal axonal localization of 5-HT1B serotonin receptors in adult rat brain. J. Comp. Neurol., 417: 181-94.
12. Scholtissen B, Verhey FRJ, Steinbusch HWM, Leentjens AFG (2006). Serotonergic mechnisms in Parkinson's disease: opposing results from preclinical and clinical data; J. Neural. Trans., 113: 59-73.
13. 11C]raclopide. Neuropgsychopharmacol. 20: 424-433.